Imricor Medical Systems, Inc. (ASX:IMR) is a U.S.-based medical device company, focused on designing, manufacturing and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Imricor believes it will be the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.
Imricor currently has 18 issued U.S. patents, 40 corresponding granted foreign patents and 2 foreign patent applications that have been allowed.
Imricor currently generates revenue from licensing IP for use in implantable devices and a contract research project in the area of MRI-guided interventions. However, given that the company has obtained CE mark approval to place one of its key products, the Advantage-MR EP Recorder/Stimulator System, on the market in the European Union, and is in the final stages of the CE mark approval process for its other key products, the Vision-MR Ablation Catheter (with an indication for treating type I atrial flutter) and the Vision-MR Dispersive Electrode, Imricor plans to establish a third revenue stream from the sale of these products. This third revenue stream is expected to become its primary revenue source, with forecast revenues of US$6.9 million for 2019.
Pay By: August 21st
List Price: $0.83
Minimum Investment: $2,000
Raising: $12-$13M AUD
Market Cap: 77M AUD
Lead Manager: Moelis Australia